Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Zolmitriptan
Glenmark Pharmaceuticals Europe Ltd
N02CC03
Zolmitriptan
5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04070401; GTIN: 5060204161469 5060204161476
2 1 Artwork No. Barcode mind when you drive or use any tools or machines. Zolmitriptan Tablets is unlikely to affect driving or using tools or machines. However, it is best to wait to see how Zolmitriptan Tablets affects you before you try these activities. ZOLMITRIPTAN TABLETS CONTAIN ASPARTAME (E951) Zolmitriptan 2.5mg orodispersible tablets contains 0.250mg of aspartame in each tablet. Zolmitriptan 5mg orodispersible tablets contains 0.500mg of aspartame in each tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. 3. HOW TO TAKE ZOLMITRIPTAN TABLETS Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. You can take Zolmitriptan Tablets as soon as a migraine headache starts. You can also take it once an attack is underway. Ÿ The usual dose is one tablet (either 2.5mg or 5mg). Ÿ You can take another tablet if the migraine is still present after two hours or if it returns within 24 hours. If the tablets did not give you enough help with your migraine, tell your doctor. Your doctor may raise the dose to 5mg or change your treatment. You are more likely to get side effects with the higher dose (5mg). DO NOT use more than the dose prescribed for you. DO NOT use more than two doses in one day. If you have been prescribed the 2.5mg tablet, the maximum daily dose is 5mg. If you have been prescribed the 5mg tablet, the maximum daily dose is 10mg. _Instruction for use_ 1. Peel the blister pack open. Do not push the tablet through the foil. 2. Place the tablet on your tongue, where it will dissolve and be swallowed with the saliva. You do not have to take a drink of water in order to swallow your tablet. IF YOU TAKE MORE ZOLMITRIPTAN TABLETS THAN YOU SHOULD If you have taken more Zolmitriptan Tablets than prescribed by your doctor, tell your doctor or go to the nearest hospital STRAIGHT AWAY. Take Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zolmitriptan 5 mg orodispersible tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 mg orodispersible tablet contains 5 mg zolmitriptan. Excipient(s) with known effect: aspartame (8mg). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Orodispersible tablet. White, round flat tablets with the diameter 9.5 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Acute treatment of migraine headache with or without aura. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of zolmitriptan to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose of zolmitriptan has been shown to be effective. If a second dose is required, it should not be taken within 2 hours of the initial dose. If a patient does not achieve satisfactory relief with 2.5 mg doses, subsequent attacks can be treated with 5 mg doses of zolmitriptan. Zolmitriptan is equally effective whenever the tablets are taken during a migraine attack; although it is advisable that zolmitriptan is taken as early as possible after the onset of migraine headache. In the event of recurrent attacks, it is recommended that the total intake of zolmitriptan in a 24-hour period should not exceed 10 mg. Zolmitriptan is not indicated for prophylaxis of migraine. _Paediatric population (Children below the age of 12 years) _ The safety and efficacy of zolmitriptan in children aged 0-12 years has not yet been established. No data are available. Use of zolmitriptan in children is therefore not recommended. _ _ _Adolescents (12 - 17 years of age) _ The efficacy of zolmitriptan was not demonstrated in a placebo controlled clinical trial for patients aged 12 to 17 years. Use of zolmitriptan in adolescents is therefore not recommended. _Elderly _ The safety and efficacy of zolmitriptan in individuals aged over 65 years have not been established. Use of zolmitriptan in the elderly is therefore not recommended. _ _ _Hepatic impairmen Read the complete document